알레르기성 결막염 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 약물 계열별, 투여 경로별, 처방 형태별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Allergic Conjunctivitis Market Summary

The global allergic conjunctivitis market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.5 billion in 2026 to USD 5.1 billion by 2033, at a CAGR of 5.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The allergic conjunctivitis market is supported by the rising prevalence of seasonal and perennial allergies, increasing exposure to environmental allergens such as pollen, dust mites, mold, and air pollution, and growing awareness of eye allergy symptoms among patients and healthcare professionals.

Changes in climate patterns and longer pollen seasons have contributed to a higher number of allergy episodes in many regions, increasing the demand for medical consultation and treatment. The market includes antihistamines, mast cell stabilizers, dual-action agents, corticosteroids, and lubricating eye drops, with prescription and over-the-counter products serving different patient needs. Pharmaceutical companies continue to focus on improving ocular formulations that provide rapid symptom relief and longer duration of action while maintaining safety for repeated use.

Retail pharmacies, hospital pharmacies, and online pharmacies play an important role in product availability. North America accounts for a significant share due to established diagnosis and treatment practices, while the Asia Pacific is witnessing steady growth supported by urbanization, rising healthcare access, increasing allergy awareness, and improving availability of ophthalmic treatments.

Global Allergic Conjunctivitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global allergic conjunctivitis market report based on disease type, drug class, route of administration, prescription type, distribution channel, and region:

• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Seasonal Allergic Conjunctivitis (SAC)
• Perennial Allergic Conjunctivitis (PAC)
• Vernal Keratoconjunctivitis (VKC)
• Atopic Keratoconjunctivitis (AKC)
• Giant Papillary Conjunctivitis (GPC)
• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Dual-Action Antihistamine & Mast Cell Stabilizers
• Mast Cell Stabilizers
• Corticosteroids
• Immunomodulators
• NSAIDs
• Vasoconstrictor Combinations
• Oral Antihistamines
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Topical Ophthalmic
• Oral
• Others
• Prescription Type Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription (Rx)
• Over the Counter (OTC)
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Prescription Type
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Allergic Conjunctivitis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Allergic Conjunctivitis Market: Disease Type Business Analysis

• 4.1. Disease Type Market Share, 2025 & 2033
• 4.2. Disease Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
• 4.4. Seasonal Allergic Conjunctivitis (SAC)
  • 4.4.1. Seasonal Allergic Conjunctivitis (SAC) Market, 2021 - 2033 (USD Million)
• 4.5. Perennial Allergic Conjunctivitis (PAC)
  • 4.5.1. Perennial Allergic Conjunctivitis (PAC) Market, 2021 - 2033 (USD Million)
• 4.6. Vernal Keratoconjunctivitis (VKC)
  • 4.6.1. Vernal Keratoconjunctivitis (VKC) Market, 2021 - 2033 (USD Million)
• 4.7. Atopic Keratoconjunctivitis (AKC)
  • 4.7.1. Atopic Keratoconjunctivitis (AKC) Market, 2021 - 2033 (USD Million)
• 4.8. Giant Papillary Conjunctivitis (GPC)
  • 4.8.1. Giant Papillary Conjunctivitis (GPC) Market, 2021 - 2033 (USD Million)

Chapter 5. Allergic Conjunctivitis Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2025 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 5.4. Dual-Action Antihistamine & Mast Cell Stabilizers
  • 5.4.1. Dual-Action Antihistamine & Mast Cell Stabilizers Market, 2021 - 2033 (USD Million)
• 5.5. Mast Cell Stabilizers
  • 5.5.1. Mast Cell Stabilizers Market, 2021 - 2033 (USD Million)
• 5.6. Corticosteroids
  • 5.6.1. Corticosteroids Market, 2021 - 2033 (USD Million)
• 5.7. Immunomodulators
  • 5.7.1. Immunomodulators Market, 2021 - 2033 (USD Million)
• 5.8. NSAIDs
  • 5.8.1. NSAIDs Market, 2021 - 2033 (USD Million)
• 5.9. Vasoconstrictor Combinations
  • 5.9.1. Vasoconstrictor Combinations Market, 2021 - 2033 (USD Million)
• 5.10. Oral Antihistamines
  • 5.10.1. Oral Antihistamines Market, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Allergic Conjunctivitis Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Topical Ophthalmic
  • 6.4.1. Topical Ophthalmic Market, 2021 - 2033 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Allergic Conjunctivitis Market: Prescription Type Business Analysis

• 7.1. Prescription Type Market Share, 2025 & 2033
• 7.2. Prescription Type Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Million)
• 7.4. Prescription (Rx)
  • 7.4.1. Prescription (Rx) Market, 2021 - 2033 (USD Million)
• 7.5. Over the Counter (OTC)
  • 7.5.1. Over the Counter (OTC) Market, 2021 - 2033 (USD Million)

Chapter 8. Allergic Conjunctivitis Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2025 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 9. Allergic Conjunctivitis Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Allergic Conjunctivitis Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. Canada Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. UK Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Brazil Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. Argentina Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Allergic Conjunctivitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Allergic Conjunctivitis Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Alcon
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Bausch + Lomb
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. AbbVie Inc. (Allergan)
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Santen Pharmaceutical Co., Ltd.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Sun Pharmaceutical Industries Ltd.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Teva Pharmaceutical Industries Ltd.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Viatris Inc.
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Harrow
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Johnson & Johnson Vision
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Nicox SA
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives
  • 10.5.11. Dr. Reddy's Laboratories Ltd.
    • 10.5.11.1. Overview
    • 10.5.11.2. Financial Performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Strategic Initiatives